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INTRODUCTION
Resistance to chemotherapeutics remains one of the most significant stumbling blocks to achieving long-term remissions in cancer therapy. While the currently available chemotherapy agents certainly induce clinical responses, cancers ultimately progress in the vast majority of cases after a period of ongoing response [1] . Multidrug resistance (MDR) to a particular agent is defined as resistance not only to other agents of the same drug class, but also to agents from structurally unrelated classes. This is often a result of overexpression of efflux pump proteins such as P-glycoprotein (P-gp; encoded by MDR1) and multidrug resistanceassociated protein (MRP) [1] . These efflux pumps limit the effectiveness of agents such as anthracyclines and taxanes by transporting them out of their site of action within tumor cells. Tumor resistance can be primary or acquired. In the case of primary resistance, there is high physiologic expression of MDR proteins in the tissue from which the tumor arises, as is seen in renal or hepatic tissues [2] . In other cases, resistance is acquired, resulting from de novo MDR protein overexpression following treatment with MDRinducing agents. Although attempts have been made to overcome MDR through treatment with reversal agents, to date these have been largely unsuccessful (for a review, see Nobili et al. [3] ).
In general, mechanisms of resistance to microtubule inhibitors (MTIs) are somewhat different from those of other drug classes in that alterations in the molecular target, tubulin, also can result in acquired resistance. For example, expression of the ␤III-tubulin isoform has been associated with poor response to taxanes in non-small cell lung carcinoma (NSCLC) [4] , ovarian cancer [5] , gastric cancer [6] , and prostate cancer [7] . Furthermore, mutations in ␤-tubulin can also prevent taxanes from binding to their target [8] , and hence from stabilizing microtubules (the mechanism of action of this class of agent). Therefore, one avenue of antineoplastic drug development has focused on identifying compounds that are less susceptible to these common drugresistance mechanisms; such agents may represent a clinically significant addition to the armamentarium of treatment options that could be used to treat drug-resistant cancer and ultimately extend survival.
One new class of agents that is of interest in this regard is the epothilones and their analogues. These are 16-member macrolides produced by the myxobacterium Sorangium cellulosum [9, 10] . Epothilones A and B, in particular, have high in vitro antitumor activity through their ability to disrupt microtubule dynamics, leading to cell-cycle arrest and apoptosis [11] . Although they share a common therapeutic target with other MTIs, the epothilones have a distinct mode of binding to tubulin that may reduce cross-resistance. Significantly, epothilones display lower susceptibility to several key mechanisms of drug resistance, such as elevated expression of MDR, overexpression of ␤III-tubulin, and ␤-tubulin mutations [12] [13] [14] , making them interesting candidates for evaluation in the clinic, especially in diseases where anthracyclines and taxanes are heavily used.
Since the initial identification of natural epothilones as antineoplastic agents, chemical modification has allowed the generation of synthetic and semisynthetic analogues with superior metabolic and pharmacokinetic properties in the clinical setting. Ixabepilone (BMS-247550, aza-epothilone B), a semisynthetic analogue of epothilone B, has a lactone-lactam modification that minimizes susceptibility to esterase degradation [15] . Ixabepilone has been shown to have clinical activity against multiple tumor types, including those resistant to common chemotherapeutic agents, and is effective in metastatic breast cancer (MBC) as monotherapy or in combination with capecitabine. This review briefly summarizes these clinical data and focuses on the preclinical characteristics of ixabepilone that allow it to overcome both primary and acquired tumor resistance.
CLINICAL ACTIVITY OF IXABEPILONE
Ixabepilone has demonstrated single-agent activity against a wide variety of solid tumors, including breast cancer (earlyand late-stage disease) [16, 17] , NSCLC [18] , pancreatic cancer [19] , renal cell cancer (RCC) [20] , prostate cancer [21] , and lymphoma [22] . The majority of these studies involved tumors that were heavily pretreated. The largest phase II trial with ixabepilone monotherapy was conducted in anthracycline-, taxane-, and capecitabine-resistant MBC patients [23] . In this population, ixabepilone (administered at a dose of 40 mg/m 2 as a 3-hour i.v. infusion every 3 weeks) produced an overall response rate (ORR) of 12% and a median progression-free survival (PFS) time of 3.1 months [23] . Ixabepilone also showed activity in another phase II trial in taxane-resistant MBC patients, with a response rate of 12% [24] . A phase II trial evaluated ixabepilone (administered at a dose of 32 mg/m 2 as a 3-hour i.v. infusion every 3 weeks or at a dose of 6 mg/m 2 as a 1-hour i.v. infusion for five consecutive days every 3 weeks) in NSCLC patients who had failed a first-line platinum-based chemotherapy regimen [18] . ORRs of 14.3% (32 mg/m 2 dose) and 11.6% (6 mg/m 2 daily ϫ 5 dose) were reported [18] .
Two additional phase II trials have evaluated the activity of ixabepilone in patients with metastatic prostate cancer. Ixabepilone monotherapy produced prostate-specific antigen (PSA) declines of Ͼ50% in 17% of patients with hormone-and taxane-refractory prostate cancer, with a median survival time of 10.4 months [25] . A second trial evaluated the activity of ixabepilone as a single agent or in combination with estramustine phosphate in chemotherapy-naïve prostate cancer patients progressing after castration. PSA declines of Ͼ50% were observed in 48% of patients treated with ixabepilone monotherapy and 68% of patients treated with the combination regimen [26] . ORRs were 32% for ixabepilone monotherapy and 48% for the combination of ixabepilone plus estramustine [26] . Efficacy results from ixabepilone trials in resistant/pretreated cancers are summarized in Table 1 . Clinical trials comparing the efficacy and safety of ixabepilone with those of taxanes are in progress in MBC patients. Nonetheless, in taxane-sensitive tumors, the activity of ixabepilone appears to be comparable with that of other chemotherapeutic agents [27] .
Ongoing or planned phase I/II studies in a range of tu- mors are investigating whether ixabepilone can also be safely combined with a variety of agents, including liposomal doxorubicin, bevacizumab, cetuximab, and epirubicin (see http://www.ClinicalTrials.gov). A phase II study in advanced breast cancer demonstrated activity and an acceptable safety profile for ixabepilone combined with capecitabine in taxane-and anthracycline-pretreated MBC patients [28] . A large, randomized, phase III trial comparing ixabepilone plus capecitabine with capecitabine monotherapy demonstrated greater efficacy for the combination with a significantly longer median PFS time (5.8 months versus 4.2 months; p Ͻ .001) and higher response rate (35% versus 14%; p Ͻ .001) [27] .
In addition to these studies in tumors with acquired resistance to chemotherapy, ixabepilone has also been shown to have activity in the treatment of cancers that are typically considered chemotherapy resistant. For example, ixabepilone has activity in RCC [20] , suggesting that this agent may represent a treatment option even for this highly refractory disease [29] that is known to be one of the tumors with the highest levels of endogenous MDR [2] . Ixabepilone also demonstrated marked activity against advanced pancreatic cancer in a phase II study, resulting in a 6-month survival rate (the primary endpoint) of 60% [19] . This disease currently has a very poor prognosis, even following treatment with gemcitabine, the current standard of care [30] .
The main toxicities typically associated with ixabepilone treatment (administered at a dose of 40 mg/m 2 every 3 weeks) are neutropenia, sensory neuropathy, fatigue, arthralgias, myalgias, and stomatitis. These adverse effects are often manageable with dose modifications/supportive therapy, and the sensory neuropathy has been reversible in most cases once treatment is modified or stopped. Various phase II studies conducted with alternative dosing of ixabepilone (administered at a dose of 6 mg/m 2 as a 1-hour i.v. infusion on days 1-5 every 3 weeks) have reported a lower rate of grade 3 or 4 sensory neuropathy. These include taxane-pretreated MBC (n ϭ 37; rate, 3%), taxane-naïve MBC (n ϭ 22; rate, 0%), and platinum-pretreated/refractory NSCLC (n ϭ 69; rate, 6%) [16, 18, 31] .
Overall survival for MBC patients has improved over the past 5 years with the introduction of multiple, new active agents [32] . However, drug-resistant disease is an increasing clinical challenge, and ixabepilone (or other members of this novel drug class) may prove to be of value in this context, based on the clinical experience to date [17, 23, 24] . The remainder of this review focuses on the characteristics of ixabepilone at a preclinical level, which may, at least in part, explain the activity observed in the clinical setting.
IXABEPILONE: IN VITRO ACTIVITY IN DRUG-RESISTANT CELL LINES
Ixabepilone is highly active in vitro, with cytotoxicity demonstrated against a panel of 21 cell lines derived from breast, lung, prostate, colon, and ovarian cancers, as well as leukemias [15] . Fifty percent inhibitory concentration values of ixabepilone in these cell lines are low, in the range of 1.4 -34.5 nM. Importantly, in vitro activity is retained in cell lines selected for resistance to paclitaxel, including the HCT116/VM46 colon and A2780Tax ovarian cancer lines, which are resistant to paclitaxel as a result of overexpression of MDR proteins [33] and a mutation in ␤-tubulin [34] , respectively. Clonogenic cell-killing experiments further demonstrate that, while paclitaxel and ixabepilone display similar cell-killing activity against paclitaxel-sensitive cell lines, ixabepilone is substantially more cytotoxic than paclitaxel against lines defined as paclitaxel resistant [15] (Table 2) . Moreover, in these paclitaxel-resistant cell lines, ixabepilone almost completely retains the antineoplastic activity it has against paclitaxel-sensitive cell lines (Table 2) .
IXABEPILONE: PRECLINICAL ACTIVITY IN VIVO
The observed in vitro activity of ixabepilone against resistant tumor cell lines is recapitulated in vivo using xenograft models with tumors derived from the cell lines described above and from other drug-resistant cell lines (Table 2 ) [15] . These include xenografts displaying acquired resistance to paclitaxel through a range of mechanisms: MDR-mediated drug efflux, ␤-tubulin mutation, and overexpression of the ␤III-tubulin isoform. For example, activity is seen in the HCT116/VM46 xenograft model (described above) and in Pat-7, which was established directly from an ovarian tumor biopsy immediately following the development of paclitaxel resistance and expresses high levels of MDR and MRP1 [15] . The in vivo activity of ixabepilone in these models is consistent with the low susceptibility of this agent to cell membrane transporters such as P-gp and MRP1 [12] . Importantly, ixabepilone does not appear to induce expression of the MDR or MRP1 genes, a characteristic that could potentially prevent the development of cross-resistance with other agents [12] . In vivo activity of ixabepilone is also seen in the A2780Tax ovarian cancer xenograft model, indicating that ixabepilone is unaffected by the specific point mutation in ␤-tubulin that confers resistance to paclitaxel in these cells. Ixabepilone also displays in vivo activity in the Pat-21 breast cancer xenograft model, which is derived from a biopsy of a tumor that was clinically resistant to paclitaxel because of overexpression of 217 Vahdat ␤III-tubulin and downregulation of the ␤II isoform [14] . Preclinical experiments have demonstrated that, unlike paclitaxel, ixabepilone can bind multiple isoforms of ␤-tubulin, including the ␤III isoform [14] . These results are consistent with the recent demonstration, through computational methods, that epothilone A displays no preference for either the ␤I-or ␤III-tubulin isoform [35] .
Importantly, in addition to the xenograft models described above, ixabepilone is also active in vivo against a pancreatic tumor xenograft displaying intrinsic insensitivity to paclitaxel [15] . This tumor xenograft, Pat-26, was derived from a liver metastasis in a pancreatic cancer patient who had never received chemotherapy, suggesting that ixabepilone may also provide clinical benefit to patients with cancers considered intrinsically resistant to the currently available agents. In all cases described above, the antitumor activity of ixabepilone (as measured by log-cell kill) was 3.0 to 5.3-fold greater than that of paclitaxel.
In summary, these findings, together with the in vitro findings described above, demonstrate that ixabepilone has high activity against a wide range of tumor types in the preclinical setting. Moreover, ixabepilone has lower susceptibility to several key mechanisms of tumor resistance. It is these two characteristics of ixabepilone that collectively underlie the clinical activity of this agent across tumor types, including heavily pretreated and drug-resistant tumors.
MODE OF ACTION OF IXABEPILONE
Like the natural epothilones A and B, ixabepilone promotes tumor cell death by stabilizing microtubules and inducing apoptosis [36] , and is a highly active MTI [15] . Significantly, ixabepilone induces apoptosis through multiple pathways that appear to be selective to this class of agents, including enhancement of caspase-2 activity [37] and p53-mediated activation of the death effector Bax via induction of PUMA (p53 upregulated modulator of apoptosis) expression [38] . In contrast, taxanes mediate apoptosis primarily via caspase 9 activation [36] . These differences in mode of action may, at least in part, underlie the activity of ixabepilone against multiple tumor types that are resistant and/or refractory to taxanes. 
FUTURE DEVELOPMENTS
The promising phase II clinical results with ixabepilone have led to two large phase III trials evaluating ixabepilone in combination with capecitabine versus capecitabine alone. The first study in patients with anthracycline-and taxane-pretreated MBC (NCT00080301) has been completed and demonstrated superior efficacy for the combination of ixabepilone plus capecitabine, with a significantly longer median PFS time and higher response rate [24] . Based on its activity, ixabepilone was approved by the U.S. Food and Drug Administration in combination with capecitabine for the treatment of patients with metastatic or locally advanced breast cancer resistant to an anthracycline and a taxane. In addition, in view of data obtained in phase II trials, ixabepilone was approved as monotherapy for the treatment of metastatic or locally advanced breast cancer in patients whose tumors are resistant or refractory to anthracyclines, taxanes, and capecitabine. A second phase III study in patients with anthracyclinepretreated, taxane-resistant MBC (NCT00082433) has completed recruitment of patients [39] . That study will examine overall survival in the taxane-resistant patient population.
Once an agent has demonstrated efficacy in the metastatic setting, it is of great interest to evaluate the same agent in earlier stages of disease, where maximum benefit can be obtained. Various studies have shown that, in the neoadjuvant setting, MDR expression may represent one of the main determinants of resistance to chemotherapy in breast cancer patients [40, 41] . Thus, early disease may provide an opportunity to assess the activity of ixabepilone in MDR-related resistant breast cancer. Ixabepilone, therefore, has also been evaluated as a single agent in the neoadjuvant setting for breast cancer [42] . A pathologic complete response in the breast (pCR B ) was observed in 18% of patients after four cycles of therapy [42] . In addition, 32% of patients were able to undergo breastconserving surgery [42] . The 18% pCR B rate reported after four cycles of ixabepilone compared favorably with the pCR B rates in studies of single-agent taxanes administered for four cycles of neoadjuvant therapy [42] .
Other epothilones are also undergoing clinical evaluation, and have been shown to have activity in the drug-resistant setting. Of these, patupilone (EPO-906, natural epothilone B) is furthest along in development. Patupilone has demonstrated preclinical in vitro and in vivo activity against a range of tumor lines [13, 43, 44] , including those overexpressing MDR proteins [11, 13, 43] . It will now be of interest to see whether this agent also retains activity against paclitaxel-resistant cell lines overexpressing ␤III-tubulin or bearing ␤-tubulin mutations, as observed for ixabepilone. Phase II studies have demonstrated the activity of patupilone against drug-resistant disease, including RCC and relapsed/refractory ovarian cancer [45, 46] , and phase III studies are in progress. Epothilone D (desoxyepothilone B; KOS-862) also has demonstrated preclinical activity against a number of MDR xenografts, including the doxorubicin-resistant breast cancer line MCF7 (see Goodin et al. [47] ). Clinically, phase II efficacy of epothilone D has been shown in anthracycline-and taxane-pretreated MBC patients [48, 49] . The fully synthetic epothilone B analogue ZK-EPO also has demonstrated in vivo preclinical activity against resistant tumor cell lines, including breast, colorectal, ovarian, lung, and pancreatic cancer, glioma, and melanoma models [50, 51] . Preliminary clinical results show that ZK-EPO has some activity in taxane-pretreated or resistant breast cancer [52] and uterine cancer [53] . In a phase II trial in patients with platinum-resistant ovarian cancer that evaluated two dosing schedules of ZK-EPO, an ORR of 19% was reported [54] . Finally, the epothilone D analogue KOS-1584 (dehydelone) has been shown to have preclinical activity against a range of tumor types, including paclitaxel-resistant lymphoblastic leukemia and NSCLC [55] . Dehydelone is at a very early stage of clinical development, but preliminary data from a phase I trial suggest that this agent led to minor responses or disease stabilization in some patients with various tumors [56, 57] .
CONCLUSIONS
Because of the high incidence of tumor resistance to available chemotherapeutic agents, there is a pressing need for new antineoplastics with efficacy in patients with drug-resistant disease. The epothilones and their analogues are a class of highly active MTIs that have low susceptibility to several mechanisms of tumor resistance. The epothilone B analogue ixabepilone has been approved as monotherapy or in combination with capecitabine for the treatment of resistant/refractory MBC and has been shown to have promising clinical activity against various other tumor types. The unique mode of binding of ixabepilone to its therapeutic target, its activation of selective apoptotic pathways, and its low susceptibility to multiple mechanisms of tumor resistance are important properties that underlie the clinical activity of this agent. The outcomes of clinical studies with other agents in this class and further clinical development of ixabepilone, including its use in earlier stages of breast cancer, are eagerly awaited.
